<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405130</url>
  </required_header>
  <id_info>
    <org_study_id>RESTORE-SIRIO</org_study_id>
    <nct_id>NCT02405130</nct_id>
  </id_info>
  <brief_title>The RESTORE-SIRIO Randomized Controlled Trial</brief_title>
  <acronym>RESTORE-SIRIO</acronym>
  <official_title>Impact of intRacoronary adrEnaline on Myocardial reperfuSion in STEMI paTients With Persistent Impaired cORonary Flow After pErcutaneous Coronary Intervention: the RESTORE-SIRIO Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SIRIO MEDICINE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for
      treating acute ST-segment elevation myocardial infarction (STEMI). The main goals are to
      restore epicardial infarct-related artery patency and to achieve microvascular reperfusion as
      early as possible. No-reflow is the term used to describe inadequate myocardial perfusion of
      a given coronary segment without angiographic evidence of persistent mechanical obstruction
      of epicardial vessels and it refers to the high resistance of microvascular blood flow
      encountered during opening of the infarct-related coronary artery.

      Despite optimal evidence-based PPCI, myocardial no-reflow can still occur, negating many of
      the benefits of restoring culprit vessel patency, and is associated with a worse in-hospital
      and long-term prognosis. Several strategies have been tested to revert the no-reflow
      including the use of thrombectomy, glycoprotein IIb/IIIa inhibitors and the use of
      intracoronary adenosine, but none has been demonstrated to effectively counteract the
      phenomenon.

      The trial aims to show the effect of the administration of intracoronary adrenalin on
      myocardial reperfusion assessed by magnetic resonance in patients with STEMI undergoing PCI
      and with persistent coronary angiographic The Thrombolysis in Myocardial Infarction (TIMI)
      0-1 flow during the interventional procedure after failure of standard therapy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>myocardial infarct size (% total LV mass)</measure>
    <time_frame>48-72 hours post intervention</time_frame>
    <description>cMRI parameters: myocardial infarct size (% total LV mass)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and extent of microvascular obstruction</measure>
    <time_frame>48-72 hours and 30 days post intervention</time_frame>
    <description>cMRI parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial salvage index (MSI)</measure>
    <time_frame>48-72 hours and 30 days post intervention</time_frame>
    <description>cMRI parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-myocardial haemorrhage (IMH)</measure>
    <time_frame>48-72 hours and 30 days post intervention</time_frame>
    <description>cMRI parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV ejection fraction (LVEF) and volumes</measure>
    <time_frame>48-72 hours and 30 days post intervention</time_frame>
    <description>cMRI parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis in Myocardial Infarction (TIMI) flow grade)</measure>
    <time_frame>48-72 hours post intervention</time_frame>
    <description>Angiographic markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial blush grade (MBG)</measure>
    <time_frame>48-72 hours post intervention</time_frame>
    <description>Angiographic markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Computer-assisted myocardial blush quantification using the software 'Quantitative Blush Evaluator' (QuBE)</measure>
    <time_frame>48-72 hours post intervention</time_frame>
    <description>Angiographic markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of ST segment resolution on ECG</measure>
    <time_frame>48-72 hours post intervention</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>creatine kinase and troponin I release</measure>
    <time_frame>48-72 hours post intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>major cardiovascular events (MACE)</measure>
    <time_frame>30 days post intervention</time_frame>
    <description>death, need for Target Lesion Revascularization, recurrent myocardial infarction (MI), new or worsening heart failure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>No-reflow Phenomen</condition>
  <condition>Acute ST-segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intracoronary epinephrine is two ampoules each of 1:1000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline (to 20 μg/mL epinephrine solution); a 5 ml syringe prepared will then contain 100 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no intracoronary epinephrine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>no epinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intracoronary epinephrine</intervention_name>
    <description>after failure of standard therapy patients will treated with epinephrine</description>
    <arm_group_label>epinephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intracoronary epinephrine</intervention_name>
    <description>patients will receive standard therapy only</description>
    <arm_group_label>no intracoronary epinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years of age

          -  presentation within 6-7 h of symptom onset of STEMI

          -  eligibility for reperfusion by primary-PCI

          -  TIMI flow grade 0-1 during the interventional procedure in the culprit vessel after
             the initial opening of the vessel with the coronary wire

        Exclusion Criteria:

          -  evident clinical arrhythmias (ventricular tachycardia/ventricular fibrillation)

          -  evidence of coronary dissection or spasm

          -  Parkinson symptoms

          -  closed angle glaucoma

          -  thyroid disorders

          -  known history to hypersensitivity to the drug

          -  pregnancy

          -  stage 4 or 5 CKD (eGFR &lt;30 mL/min/1.73 m2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliano P Navarese, MD, PhD, FESC</last_name>
    <role>Study Director</role>
    <affiliation>Division of Cardiology, Pulmonary Disease and Vascular Medicine, Heinrich-Heine University Dusseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonary Disease and Vascular Medicine</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uniklinik-duesseldorf.de/kardiologie</url>
  </link>
  <link>
    <url>http://siriomedicine.com/</url>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

